Permanent Consequences of Langerhans Cell Histiocytosis. Experience of an Observational Trial

被引：0
|
作者：
Bronin, Gleb [1 ]
Miroshkin, Roman [1 ]
Bezunov, Evgeniy [1 ]
Mironova, Elizaveta [1 ]
Fisun, Elena [1 ]
Kurmanov, Bulat [1 ]
Promyslova, Elena [1 ]
Kasatkin, Vladimir [1 ]
Karelin, Alexander [1 ]
机构：
[1] Fed Ctr Pediat Hematol, Moscow, Russia
来源：
PEDIATRIC BLOOD & CANCER | 2016年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [31] CNS involvement of Langerhans cell histiocytosis. Report of 23 surgically treated cases
    Belen, D
    Colak, A
    Ozcan, OE
    NEUROSURGICAL REVIEW, 1996, 19 (04) : 247 - 252
  • [32] HIGH EFFICACY OF THE MACOP-B REGIMEN IN THE TREATMENT OF ADULT LANGERHANS CELL HISTIOCYTOSIS. A 20-YEAR EXPERIENCE
    Derenzini, E.
    Stefoni, V.
    Pellegrini, C.
    Gandolfi, L.
    Broccoli, A.
    Casadei, B.
    Quirini, F.
    Argnani, L.
    Tonialini, L.
    Cavo, M.
    Zinzani, P. L.
    HAEMATOLOGICA, 2015, 100 : 92 - 93
  • [33] Cytogenetic abnormalities in PHA-stimulated lymphocytes from patients with Langerhans cell histiocytosis.
    Danesino, C
    Scappaticci, S
    Klersy, C
    Vallinoto, C
    Ziino, O
    Russo, D
    Allen, M
    Defilippi, P
    Clementi, R
    Aricò, M
    BLOOD, 2001, 98 (11) : 151B - 152B
  • [34] Permanent disabilities in childhood survivors of Langerhans cell histiocytosis
    Kusumakumary, P
    James, FV
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2000, 17 (05) : 375 - 381
  • [35] RISK FACTOR ANALYSIS AT DIAGNOSIS IN LANGERHANS CELL HISTIOCYTOSIS. IMPORTANCE OF BICYTOPENIA, TRICYTOPENIA AND HYPOALBUMINEMIA
    Braier, Jorge
    Rosso, Diego
    Chantada, Guillermo
    Latella, Antonio
    Scopinaro, Marcelo
    PEDIATRIC BLOOD & CANCER, 2009, 53 (04) : 685 - 685
  • [36] Langerhans cell histiocytosis.: Clinical study and long-term evolution in 21 patients
    Morell, F
    Reyes, L
    Majó, J
    Orriols, R
    Román, A
    MEDICINA CLINICA, 2000, 115 (02): : 60 - 64
  • [37] Initial clinical results with In-111 pentreotide imaging in patients with Langerhans' cell histiocytosis.
    Weinmann, P
    Tazi, A
    Crestani, B
    Genereau, T
    Aubier, M
    Valeyre, D
    Moretti, JL
    Le Guludec, D
    Lebtahi, R
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09): : 1039 - 1039
  • [38] Interest of thalidomide in cutaneo-mucous and hypothalamo-hypophyseal in Langerhans cell histiocytosis.
    Claudon, A
    Dietemann, JL
    De Compte, AH
    Hassler, P
    REVUE DE MEDECINE INTERNE, 2002, 23 (07): : 651 - 656
  • [39] Presence of abnormal circulating CD34+ progenitors in adult Langerhans cell histiocytosis.
    Misery, L
    Rougier, N
    Faure, M
    Claudy, A
    Schmitt, D
    Vincent, C
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (04) : 566 - 566
  • [40] BRAFV600E frequency and impact on outcomes in adults with langerhans cell histiocytosis.
    Acosta-Medina, Aldo A.
    Abeykoon, Jithma P.
    Bennani, N. Nora
    Davidge-Pitts, Caroline
    Koster, Matthew J.
    Ravindran, Aishwarya
    Rech, Karen
    Ryu, Jay H.
    Schram, Susan M.
    Shah, Mithun Vinod
    Tobin, W. Oliver
    Vassallo, Robert
    Young, Jason R.
    Go, Ronald S.
    Goyal, Gaurav
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345